Antiparasitic agent atovaquone.
作者信息
Baggish Aaron L, Hill David R
机构信息
University of Connecticut School of Medicine, Farmington, Connecticut, USA.
出版信息
Antimicrob Agents Chemother. 2002 May;46(5):1163-73. doi: 10.1128/AAC.46.5.1163-1173.2002.
Abstract
摘要
相似文献
1
Antiparasitic agent atovaquone.抗寄生虫药阿托伐醌。
Antimicrob Agents Chemother. 2002 May;46(5):1163-73. doi: 10.1128/AAC.46.5.1163-1173.2002.
2
Criteria for use of atovaquone oral suspension in adult inpatients and outpatients.阿托伐醌口服混悬液在成人住院患者和门诊患者中的使用标准。
Am J Health Syst Pharm. 1995 Nov 1;52(21):2460-2. doi: 10.1093/ajhp/52.21.2460.
3
Evaluation of the activities of rifabutin combined with atovaquone or low-dose of cotrimoxazole for prevention of pneumocystosis and toxoplasmosis in a dual infection rat model.利福布汀联合阿托伐醌或低剂量复方新诺明预防双重感染大鼠模型中肺孢子虫病和弓形虫病的活性评估。
J Eukaryot Microbiol. 1996 Sep-Oct;43(5):14S-15S. doi: 10.1111/j.1550-7408.1996.tb04955.x.
4
Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections.阿托伐醌。对其药理特性及在机会性感染中的治疗效果的综述。
Drugs. 1995 Jul;50(1):176-96. doi: 10.2165/00003495-199550010-00011.
5
Atovaquone.阿托伐醌。
J Assoc Nurses AIDS Care. 1993 Apr-Jun;4(2):60-2.
6
The role of atovaquone tablets in treating Pneumocystis carinii pneumonia.阿托伐醌片在治疗卡氏肺孢子虫肺炎中的作用。
J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Mar 1;8(3):247-52. doi: 10.1097/00042560-199503010-00005.
7
Atovaquone for Pneumocystis carinii pneumonia.阿托伐醌用于卡氏肺孢子虫肺炎。
Med Lett Drugs Ther. 1993 Apr 2;35(893):28-9.
8
Atovaquone for Pneumocystis carinii pneumonia.阿托伐醌用于卡氏肺孢子虫肺炎。
Ann Intern Med. 1995 Feb 15;122(4):314; author reply 314-5. doi: 10.7326/0003-4819-122-4-199502150-00015.
9
Atovaquone for Pneumocystis carinii pneumonia.阿托伐醌用于卡氏肺孢子虫肺炎。
Ann Intern Med. 1995 Feb 15;122(4):314; author reply 314-5. doi: 10.7326/0003-4819-122-4-199502150-00014.
10
Atovaquone to be marketed as oral therapy for Pneumocystis carinii pneumonia.阿托伐醌将作为卡氏肺孢子虫肺炎的口服治疗药物上市。
Clin Pharm. 1993 Mar;12(3):175-6.
引用本文的文献
1
MEDT insights into the mechanism and selectivity of the (3 + 2) cycloaddition of ()--methyl--(2-furyl)-nitrone with but-2-ynedioic acid and the bioactivity of the reaction products.MEDT对（）-甲基-（2-呋喃基）-硝酮与丁-2-炔二酸的（3 + 2）环加成反应的机理和选择性以及反应产物生物活性的见解。
RSC Adv. 2025 Sep 8;15(39):32271-32283. doi: 10.1039/d5ra04143k. eCollection 2025 Sep 5.
2
The emerging role of Imatinib in malaria management: a review of evidence and future directions.伊马替尼在疟疾治疗中的新作用：证据综述与未来方向
Trop Dis Travel Med Vaccines. 2025 Aug 15;11(1):28. doi: 10.1186/s40794-025-00257-0.
3
Pinosylvin: A Multifunctional Stilbenoid with Antimicrobial, Antioxidant, and Anti-Inflammatory Potential.松二苯乙烯：一种具有抗菌、抗氧化和抗炎潜力的多功能芪类化合物。
Curr Issues Mol Biol. 2025 Mar 18;47(3):204. doi: 10.3390/cimb47030204.
4
Metal(triphenylphosphine)-atovaquone Complexes: Synthesis, Antimalarial Activity, and Suppression of Heme Detoxification.金属（三苯基膦）-阿托伐醌配合物：合成、抗疟活性及对血红素解毒的抑制作用
Inorg Chem. 2024 Sep 16;63(37):17087-17099. doi: 10.1021/acs.inorgchem.4c02751. Epub 2024 Aug 26.
5
Efficacy and mechanism of energy metabolism dual-regulated nanoparticles (atovaquone-albendazole nanoparticles) against cystic echinococcosis.能量代谢双重调控纳米粒（阿托伐醌-阿苯达唑纳米粒）抗包虫病的疗效及机制。
BMC Infect Dis. 2024 Aug 3;24(1):778. doi: 10.1186/s12879-024-09662-w.
6
The Establishment of a Novel In Vitro System for Culturing .一种新型体外培养系统的建立
Pathogens. 2024 Jul 4;13(7):565. doi: 10.3390/pathogens13070565.
7
Proguanil Suppresses Breast Tumor Growth In Vitro and In Vivo by Inducing Apoptosis via Mitochondrial Dysfunction.氯胍通过线粒体功能障碍诱导细胞凋亡，从而在体外和体内抑制乳腺肿瘤生长。
Cancers (Basel). 2024 Feb 22;16(5):872. doi: 10.3390/cancers16050872.
8
Onchocerciasis Drug Discovery: In Vitro Evaluation of FDA-Approved Drugs against in Gambia.盘尾丝虫病药物研发：针对冈比亚的美国食品药品监督管理局批准药物的体外评估
Pharmaceutics. 2024 Jan 31;16(2):210. doi: 10.3390/pharmaceutics16020210.
9
Enhancing radiotherapy outcomes in rectal cancer: A systematic review of targeting hypoxia-induced radioresistance.提高直肠癌放疗效果：针对缺氧诱导的放射抗性的系统评价
Clin Transl Radiat Oncol. 2023 Oct 28;44:100695. doi: 10.1016/j.ctro.2023.100695. eCollection 2024 Jan.
10
Inclusion complex of O-allyl-lawsone with 2-hydroxypropyl-β-cyclodextrin: Preparation, physical characterization, antiparasitic and antifungal activity.姜黄素-O-丙烯基衍生物与 2-羟丙基-β-环糊精的包合物：制备、物理特性、抗寄生虫和抗真菌活性。
J Bioenerg Biomembr. 2023 Jun;55(3):233-248. doi: 10.1007/s10863-023-09970-x. Epub 2023 Jul 14.
本文引用的文献
1
Atovaquone and proguanil hydrochloride for prophylaxis of malaria.阿托伐醌和盐酸氨丙啉用于疟疾预防。
J Travel Med. 1999 May;6 Suppl 1:S21-7.
2
Atovaquone and proguanil hydrochloride for treatment of malaria.阿托伐醌和盐酸氨苯砜用于疟疾治疗。
J Travel Med. 1999 May;6 Suppl 1:S18-20.
3
Clinical pharmacology of atovaquone and proguanil hydrochloride.阿托伐醌和盐酸氨丙啉的临床药理学。
J Travel Med. 1999 May;6 Suppl 1:S13-7.
4
Atovaquone and proguanil hydrochloride: a review of nonclinical studies.阿托伐醌和盐酸氨丙啉：非临床研究综述。
J Travel Med. 1999 May;6 Suppl 1:S8-12.
5
Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.1992 - 1997年艾滋病界定机会性感染监测
MMWR CDC Surveill Summ. 1999 Apr 16;48(2):1-22.
6
Malaria surveillance--United States, 1998.疟疾监测——美国，1998年
MMWR CDC Surveill Summ. 2001 Dec 7;50(5):1-20.
7
Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model.阿托伐醌-氯胍（malarone）在人体激发试验模型中的因果预防疗效。
Trans R Soc Trop Med Hyg. 2001 Jul-Aug;95(4):429-32. doi: 10.1016/s0035-9203(01)90206-8.
8
Plasmodium falciparum: the effects of atovaquone resistance on respiration.恶性疟原虫：阿托伐醌耐药性对呼吸的影响。
Exp Parasitol. 2001 Aug;98(4):180-7. doi: 10.1006/expr.2001.4639.
9
Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study.阿托伐醌-氯胍与甲氟喹用于非免疫旅行者疟疾预防的随机双盲研究结果
Clin Infect Dis. 2001 Oct 1;33(7):1015-21. doi: 10.1086/322694. Epub 2001 Sep 5.
10
Guidelines for malaria prevention in travellers from the United Kingdom for 2001.2001年英国旅行者疟疾预防指南。
Commun Dis Public Health. 2001 Jun;4(2):84-101.
Zotero 插件